FDA recently published the most recent Drug Trials Snapshot highlighting TROGARZO. Approved on March 6 for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults who:
The information provided in the TROGARZO Snapshots highlights who participated in the clinical trials that supported the FDA approval of this drug, and whether there were differences among sex, race and age groups. The “MORE INFO” bar shows more detailed, technical content for each section.
The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the TROGARZO. Please visit FDA Drug Trial Snapshots Database to readmore information on TROGARZO and find information on other approved drugs.
- have received several anti-HIV-1 regimens in the past,
- have HIV-1 virus that is not responding to many antiretroviral medicines,
- who are failing their current antiretroviral therapy.
The information provided in the TROGARZO Snapshots highlights who participated in the clinical trials that supported the FDA approval of this drug, and whether there were differences among sex, race and age groups. The “MORE INFO” bar shows more detailed, technical content for each section.The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the TROGARZO. Please visit FDA Drug Trial Snapshots Database to readmore information on TROGARZO and find information on other approved drugs.
Steve Morin
Office of Health and Constituent Affairs
Food and Drug Administration
Food and Drug Administration
Visit the FDA Patient Network for more Information about the HIV Liaison Program
.png)
No hay comentarios:
Publicar un comentario